Advertisement

Herz

, Volume 40, Issue 1, pp 16–24 | Cite as

Frequenz- und Rhythmuskontrolle bei Vorhofflimmern

Medikamentöse Ansätze
  • K.F. WeipertEmail author
  • D. Erkapic
  • J. Schmitt
Schwerpunkt

Zusammenfassung

Vorhofflimmern ist mit einer Prävalenz von 1–2% die häufigste Rhythmusstörung und wird aufgrund der zunehmenden Lebenserwartung in der Gesamtbevölkerung zukünftig weiter ansteigen. Die medikamentöse Therapie ist dabei wichtiger Bestandteil der Behandlung von Vorhofflimmerpatienten. Unabhängig von einer angepassten Thrombembolieprophylaxe kann eine frequenz- oder rhythmuskontrollierende Therapie verfolgt werden. Beide Ansätze haben vor allem eine Symptomverbesserung zum Ziel, da keine definitiven Vorteile hinsichtlich der Prognose nachgewiesen werden konnten. Auch ist häufig ein begleitender Einsatz von Antiarrhythmika zur Katheterablation vonnöten. Aufgrund der variierenden Wirkungsweisen, der individuellen pharmakologischen Interaktionen sowie den damit verbundenen, teilweise schwerwiegenden Nebenwirkungen ist eine ausgeprägte Kenntnis der Antiarrhythmika unerlässlich.

Schlüsselwörter

Vorhofflimmern Medikamentöse Therapie Antiarrhythmika Frequenzkontrolle Rhythmuskontrolle 

Rate and rhythm control in atrial fibrillation

Pharmacological approaches

Abstract

Atrial fibrillation is the most common form of cardiac arrhythmia, occurring in 1–2 % of the population and due to an increased life expectancy the prevalence will increase further. Pharmacological treatment of atrial fibrillation is an important component of basic initial therapeutic options for patients with atrial fibrillation. Independent of an individually adjusted prevention of thromboembolism, rate and rhythm management can also be carried out. While rate control mainly applies to all patients, rhythm control is only indicated in patients who remain clinically symptomatic despite sufficient rate control. Profound knowledge about antiarrhythmic drugs including specific interactions is necessary due to the variable individual effects and sometimes severe side effects.

Keywords

Atrial fibrillation Pharmacological therapy Antiarrhythmic agents Rate control Rhythm control 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt. K.F. Weipert, D. Erkapic und J. Schmitt geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Camm AJ, Lip GYH, De Caterina R et al (2013) Corrigendum to: ‘2012 focused update of the ESC Guidelines for the management of atrial fibrillation’ [Eur Heart J (2012); 33(21):2719–2747]. Eur Heart J 34:790CrossRefGoogle Scholar
  2. 2.
    Alboni P, Botto GL, Baldi N et al (2004) Outpatient treatment of recent-onset atrial fibrillation with the „pill-in-the-pocket“ approach. N Engl J Med 351:2384–2391CrossRefPubMedGoogle Scholar
  3. 3.
    Camm AJ, Capucci A, Hohnloser SH et al (2011) A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 57:313–321CrossRefPubMedGoogle Scholar
  4. 4.
    Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–2429CrossRefPubMedGoogle Scholar
  5. 5.
    Camm AJ, Lip GY, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747CrossRefPubMedGoogle Scholar
  6. 6.
    Cappato R, Ezekowitz MD, Klein AL et al (2014) Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 35:3346–3355CrossRefPubMedGoogle Scholar
  7. 7.
    Carlsson J, Miketic S, Windeler J et al (2003) Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41:1690–1696CrossRefPubMedGoogle Scholar
  8. 8.
    Chun KR, Bordignon S, Urban V et al (2013) Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. Heart Rhythm 10:1792–1799CrossRefPubMedGoogle Scholar
  9. 9.
    Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA (1998) Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 81:594–598CrossRefPubMedGoogle Scholar
  10. 10.
    Connolly SJ (1999) Evidence-based analysis of amiodarone efficacy and safety. Circulation 100:2025–2034CrossRefPubMedGoogle Scholar
  11. 11.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151CrossRefPubMedGoogle Scholar
  12. 12.
    Cotter G, Blatt A, Kaluski E et al (1999) Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study. Eur Heart J 20:1833–1842CrossRefPubMedGoogle Scholar
  13. 13.
    Dorian P, Jung W, Newman D et al (2000) The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 36:1303–1309CrossRefPubMedGoogle Scholar
  14. 14.
    Fedida D, Orth PM, Chen JY et al (2005) The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 16:1227–1238CrossRefPubMedGoogle Scholar
  15. 15.
    Flaker G, Lopes RD, Al-Khatib SM et al (2014) Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 63:1082–1087CrossRefPubMedGoogle Scholar
  16. 16.
    Friberg L (2014) Safety of dronedarone in routine clinical care. J Am Coll Cardiol 63:2376–2384CrossRefPubMedGoogle Scholar
  17. 17.
    Glatter KA, Dorostkar PC, Yang Y et al (2001) Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation 104:1933–1939CrossRefPubMedGoogle Scholar
  18. 18.
    Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370–2375CrossRefPubMedGoogle Scholar
  19. 19.
    Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992CrossRefPubMedGoogle Scholar
  20. 20.
    Hamer ME, Blumenthal JA, McCarthy EA et al (1994) Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am J Cardiol 74:826–829CrossRefPubMedGoogle Scholar
  21. 21.
    Harris L, McKenna WJ, Rowland E et al (1983) Side effects of long-term amiodarone therapy. Circulation 67:45–51CrossRefPubMedGoogle Scholar
  22. 22.
    Hernandez-Madrid A, Svendsen JH, Lip GY et al (2013) Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. Europace 15:915–918CrossRefPubMedGoogle Scholar
  23. 23.
    Hohnloser SH, Crijns HJ, Eickels M van et al (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360:668–678CrossRefPubMedGoogle Scholar
  24. 24.
    Hohnloser SH, Loo A van de, Baedeker F (1995) Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 26:852–858CrossRefPubMedGoogle Scholar
  25. 25.
    Holmes DR, Reddy VY, Turi ZG et al (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374:534–542CrossRefPubMedGoogle Scholar
  26. 26.
    Humphries KH, Kerr CR, Connolly SJ et al (2001) New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 103:2365–2370CrossRefPubMedGoogle Scholar
  27. 27.
    Hylek EM, Go AS, Chang Y et al (2003) Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:1019–1026CrossRefPubMedGoogle Scholar
  28. 28.
    Kaab S, Hinterseer M, Nabauer M, Steinbeck G (2003) Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome – a case-control pilot study using i.v. sotalol. Eur Heart J 24:649–657CrossRefPubMedGoogle Scholar
  29. 29.
    Kafkas NV, Patsilinakos SP, Mertzanos GA et al (2007) Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter. Int J Cardiol 118:321–325CrossRefPubMedGoogle Scholar
  30. 30.
    Kerr CR, Humphries K (2005) Gender-related differences in atrial fibrillation. J Am Coll Cardiol 46:1307–1308CrossRefPubMedGoogle Scholar
  31. 31.
    Khan IA (2001) Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 37:542–547CrossRefPubMedGoogle Scholar
  32. 32.
    Kirchhof P, Auricchio A, Bax J et al (2007) Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 28:2803–2817CrossRefPubMedGoogle Scholar
  33. 33.
    Kirchhof P, Franz MR, Bardai A, Wilde AM (2009) Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. J Am Coll Cardiol 54:143–149CrossRefPubMedGoogle Scholar
  34. 34.
    Klein AL, Grimm RA, Murray RD et al (2001) Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344:1411–1420CrossRefPubMedGoogle Scholar
  35. 35.
    Kober L, Torp-Pedersen C, McMurray JJ et al (2008) Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358:2678–2687CrossRefPubMedGoogle Scholar
  36. 36.
    Kochiadakis GE, Igoumenidis NE, Parthenakis FI et al (1999) Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 33:966–971CrossRefPubMedGoogle Scholar
  37. 37.
    Kowey PR, Dorian P, Mitchell LB et al (2009) Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2:652–659CrossRefPubMedGoogle Scholar
  38. 38.
    Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF (2007) Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 4:CD005049PubMedGoogle Scholar
  39. 39.
    Lloyd-Jones DM, Wang TJ, Leip EP et al (2004) Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110:1042–1046CrossRefPubMedGoogle Scholar
  40. 40.
    Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A et al (2000) Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 86:950–953CrossRefPubMedGoogle Scholar
  41. 41.
    Nagarakanti R, Ezekowitz MD, Oldgren J et al (2011) Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123:131–136CrossRefPubMedGoogle Scholar
  42. 42.
    Nokin P, Clinet M, Schoenfeld P (1983) Cardiac beta-adrenoceptor modulation by amiodarone. Biochem Pharmacol 32:2473–2477CrossRefPubMedGoogle Scholar
  43. 43.
    Ogawa S, Yamashita T, Yamazaki T et al (2009) Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 73:242–248CrossRefPubMedGoogle Scholar
  44. 44.
    Opolski G, Torbicki A, Kosior DA et al (2004) Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 126:476–486CrossRefPubMedGoogle Scholar
  45. 45.
    Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891CrossRefPubMedGoogle Scholar
  46. 46.
    Pollak PT (1999) Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol 84:37R–45RCrossRefPubMedGoogle Scholar
  47. 47.
    Reisinger J, Gatterer E, Lang W et al (2004) Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J 25:1318–1324CrossRefPubMedGoogle Scholar
  48. 48.
    Roy D, Pratt CM, Torp-Pedersen C et al (2008) Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117:1518–1525CrossRefPubMedGoogle Scholar
  49. 49.
    Roy D, Talajic M, Nattel S et al (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2677CrossRefPubMedGoogle Scholar
  50. 50.
    Salgado HC, Simoes GM, Santana Filho VJ et al (2007) Negative inotropic and lusitropic effects of intravenous amiodarone in conscious rats. Clin Exp Pharmacol Physiol 34:870–875CrossRefPubMedGoogle Scholar
  51. 51.
    Savelieva I, Graydon R, Camm AJ (2014) Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. Europace 16:162–173CrossRefPubMedGoogle Scholar
  52. 52.
    Sehgal V, Bajwa SJ (2014) European Heart and Rhythm Association guidelines on new oral anticoagulants: a bold step forward. J Pharmacol Pharmacother 5:167–169CrossRefPubMedCentralPubMedGoogle Scholar
  53. 53.
    Shulkin BL, Peele ME, Utiger RD (1984) Beta-adrenergic antagonist inhibition of hepatic 3,5,3’-triiodothyronine production. Endocrinology 115:858–861CrossRefPubMedGoogle Scholar
  54. 54.
    Simonian SM, Lotfipour S, Wall C, Langdorf MI (2010) Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation. Intern Emerg Med 5:421–426CrossRefPubMedGoogle Scholar
  55. 55.
    Singh BN, Connolly SJ, Crijns HJ et al (2007) Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357:987–999CrossRefPubMedGoogle Scholar
  56. 56.
    Singh BN, Singh SN, Reda DJ et al (2005) Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352:1861–1872CrossRefPubMedGoogle Scholar
  57. 57.
    Stambler BS, Wood MA, Ellenbogen KA (1997) Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation 96:4298–4306CrossRefPubMedGoogle Scholar
  58. 58.
    Stewart S, Hart CL, Hole DJ, McMurray JJ (2001) Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 86:516–521CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Van Gelder IC, Groenveld HF, Crijns HJ et al (2010) Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362:1363–1373CrossRefGoogle Scholar
  60. 60.
    Van Gelder IC, Hagens VE, Bosker HA et al (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834–1840CrossRefGoogle Scholar
  61. 61.
    Wyse DG, Waldo AL, DiMarco JP et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833CrossRefPubMedGoogle Scholar

Copyright information

© Urban & Vogel 2015

Authors and Affiliations

  1. 1.Medizinische Klinik I – KardiologieUniversitätsklinik GießenGießenDeutschland

Personalised recommendations